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Background. Sympathetic overactivity has been linked to vasospastic angina (VSA),
although the exact pathophysiology of VSA is poorly understood. The purpose of this
study is to assess if renal sympathetic denervation (RDN) reduces cardiac sympathetic
nerve activity with a subsequent beneficial effect on angina relief in patients with
refractory VSA.
Methods and results. Cardiac sympathetic nerve activity was assessed prior to proce-
dure and at 6 months post-procedure using iodine-123 labeled meta-iodobenzylguanidine
(123I-MIBG) imaging. The Seattle Angina questionnaire (SAQ) was used to assess the degree
to which the disease impacts quality of life. No significant change was observed in early
HMR (pre-RDN: 2.74 [2.10 to 3.21] vs 6 months post-RDN: 2.57 [2.20 to 3.00]; P = 0.76),
and late HMR (pre-RDN: 2.56 [2.18 to 3.20] vs 6 months post-RDN: 2.36 [2.13 to 3.22]; P =
0.22). Additionally, no change was seen in WR (P = 0.22). SAQ results revealed significant
improvements in perceived physical limitation, angina frequency, and quality of life at 6
months (P < 0.05 for all).
Conclusion. RDN resulted in improvements in angina class and quality of life at 6
months in patients with refractory VSA. RDN, however, did not result in significant changes
in cardiac sympathetic nerve activity as measured using 123I-MIBG. The latter observation
should be considered with caution given the small sample size of this study. Larger studies
are needed to assess this further. (J Nucl Cardiol 2020;27:2202–9.)
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Vasospastic angina (VSA) is a clinical syndrome
that was first described by Prinzmetal et al. in 1959.1
Although the syndrome has been characterized by
episodes of coronary artery vasospasm, the exact patho-
physiology of spasms is poorly understood. While
studies from the early ‘80s and ‘90s already demon-
strated that both the sympathetic and parasympathetic
nervous system are responsible for coronary vasomo-
tion, more recent work demonstrated significant
hyperactivity of the sympathetic nervous system (SNS)
in patients with VSA as compared to healthy controls.2–4
The majority of VSA patients present with refractory
angina; however, the disease appears not benign. Syn-
cope and ventricular arrhythmias are the first clinical
presentation in up to 40% of the cases and the risk for
sudden death may be increased by up to 50%.5–8 Current
treatment options are mainly pharmacological and
include the use of long-acting nitrates and calcium
channel blockers, which showed to provide symptom
improvement in 30 to 80% of the cases, respectively.9
Looking for more effective treatments, several small
studies showed that surgical (cardiac) sympathetic
denervation resulted in a significantly lower number of
angina episodes and ST-segment deviations on 24h
holter monitoring.10,11 In the present study, we hypoth-
esized that renal sympathetic denervation (RDN), a
percutaneous treatment that proved to significantly
lower blood pressure and systemic sympathetic nerve
activity in hypertensive patients, might provide addi-
tional angina relief in patients with VSA. In order to
quantify the potential effect of RDN on cardiac sympa-
thetic nerve activity, iodine-123-labeled meta-
iodobenzylguanidine (123I-MIBG) scintigraphy was
used.12,13
METHODS
Study Population and Endpoints
Between April 2013 and August 2016, a total of 10
consecutive patients with refractory VSA underwent RDN.
Patients were eligible in case of refractory angina. Significant
residual coronary artery stenosis was ruled out and patency of
previously implanted stents was confirmed in all cases by
recent coronary angiography. Coronary physiologic assess-
ment using fractional flow reserve was used in case of
intermediate lesions.
VSA was confirmed in case of spontaneous or methyler-
gonovine-induced spasms with ST-segment changes and
symptoms of chest pain in 6 out of 10 patients. In 4 patients,
the diagnosis was based on the presence of recurrent episodes
of non-exercise-induced angina, which resolved after sublin-
gual nitrates and in the absence of significant atherosclerotic
coronary artery disease.
Patients were screened for RDN and followed according
to routine clinical practice. Work-up included 24h ambulatory
blood pressure measurement (24h ABPM), laboratory analysis,
echocardiography, and CT (N = 2), MRI (N = 7) or renal
duplex (N = 1) to confirm renal artery eligibility.
Follow-up in the outpatient clinic at 1, 3, and 6 months
post-RDN included 24h ABPM (at 3 and 6 months) and
echocardiography (at 6 months). Renal function was assessed
at baseline and at follow-up. Renal artery imaging was
performed at 6 months to confirm renal artery patency.
For the purpose of this, study patients were not subjects
to acts, neither was any mode of behavior imposed,
otherwise than as part of their regular treatment. Therefore,
according to Dutch law, written informed consent for study
enrolment was obtained. This study was conducted accord-
ing to the privacy policy of the Erasmus Medical Center and
the Erasmus Medical Center regulations for the appropriate
use of data in patient-orientated research, which are based
on international regulations, including the Declaration of
Helsinki. All patients consented to the use of their data for
scientific research.
The primary efficacy endpoint was the change in cardiac
sympathetic nerve activity as measured using 123I-MIBG
imaging at 6 months post-RDN, as compared to pre-RDN
(baseline). The primary safety endpoint was defined as the
occurrence of cardiovascular death, stroke, major access site
bleeding, and acute kidney injury or renal artery stenosis at 6-
month follow-up.
Secondary endpoints included the changes in Cana-
dian Cardiovascular Society grading (CCS class), blood
pressure (24h ABPM and office blood pressure), and heart
rate. The Seattle Angina Questionnaire (SAQ) was used to
assess the quality of life and signs and symptoms of
angina.
See related editorial, pp. 2210–2215
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123I-MIBG Scintigraphy Data Acquisition
and Analysis
123I-MIBG is a physiologic analog of norepinephrine and
acts selectively on sympathetic nerve endings. By using
cardiac neurotransmission imaging, global information about
neuronal function can be expressed in early, but more
specifically in late HMR (reflecting the storage regional
distribution and release of 123I-MIBG), with washout rate
(WR) reflecting the neuronal integrity or sympathetic tone.14 In
order to block thyroid uptake of free radioactive iodide, 200
mg potassium iodide (10% solution) was administered. After
30 minutes, 185 MBq 123I-MIBG was administered intra-
venously. Early and late (i.e., 15 minutes and 4 hours after
tracer injection, respectively) anterior planar scintigraphic
images were acquired for 10 minutes with a zoom factor of 1.0
and stored in a 256 9 256 matrix. Patients were imaged in a
supine position with a dual head gamma camera (Symbia T,
Siemens, Erlangen, Germany), using a medium energy colli-
mator. An energy window of ± 10% was symmetrically
centered around the 159-KeV 123I photo peak. Offline
processing software (Hermes Medical Solutions Workstation)
was used to draw a round region of interest (ROI) with fixed
diameter over the upper mediastinum, below the thyroid gland
(Figure 1). Additionally, a manual ROI over the heart was
drawn, carefully excluding adjacent activity in the liver and
lung. The left ventricular cavity was included in the myocar-
dial ROI. The MIBG images were scored by a dedicated
nuclear medicine specialist blinded to the timing of the scan.
The HMR was computed by dividing the average number of
counts within the cardiac ROI by the average number of counts
within the mediastinal ROI. Calculation of WR was performed
using the following formula (no correction for background):
WR= (HMRearly - HMRlate)/(HMRearly) 9 100%.
15
RDN Procedure
Pre-procedurally, 100IU heparin/kg was administered to
achieve an active clotting time[ 250 seconds. All procedures
were performed under conscious sedation. After administration
of local anesthesia, common femoral artery access was
achieved by an ultrasound-guided puncture and a 7-Fr sheath
was then introduced. A 7-Fr guiding catheter was used to
accommodate the ParadiseTM RDN catheter (ReCor Medical,
Palo Alto, CA).16 After smoothly engaging the renal arteries
by using a no-touch technique with the help of a standard high-
torque BHW coronary guidewire, selective renal artery
angiograms were made. The ParadiseTM system ablation
catheter was then advanced over the BHW wire. The
Figure 1. Example of MIBG image scoring with early and late HMR. Early HMR at baseline (A1)
was 3.11 and changed to 3.35 at 6 months (A2), while late HMR at baseline was 3.23 (B1) and
changed to 3.51 at 6-month (B2) follow-up. (A) 15 min after tracer injection, (B) 4 h after tracer
injection.
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ParadiseTM catheter has a distal balloon which is pressurized
by the Paradise system to a range of 1.5 to 2.0 ATM using
sterile circulating water. The ultrasound transducer is located
within the balloon (balloon diameters 5 to 8 mm). A total of 2
to 3 ultrasound emissions of 6 to 10 seconds each were
delivered per artery.
Statistical Analysis
Continuous variables were expressed as mean ± standard
deviation (SD). Continuous variables were compared using
Student’s t test. Categorical variables were expressed as
percentages and were compared using the v2 test or Fisher’s
Exact test when appropriate. Early and late HMR and WR
were compared using the Wilcoxon signed-rank test. All
statistical tests are 2-tailed. A P value\ 0.05 was considered
statistically significant. Statistical analysis was performed
using SPSS statistical analysis (version 22.0).
RESULTS
Study Population
Mean age of the patients was 57 ± 11 years, 90%
were male, and 90% were in CCS class III or IV. None
of the patients had diabetes, and hypertension was
present in 80% of the cases.
All patients were using anti-anginal therapy using
long-acting nitrates (10/10) and calcium channel block-
ers (8/10). Most patients had a history of prior coronary
revascularization (Table 1).
Primary Efficacy Endpoint
123I-MIBG change. No significant change was
observed in early HMR (pre-RDN: 2.74 [2.10 to 3.21] vs
6 months post-RDN: 2.57 [2.20 to 3.00]; P = 0.76) and
in late HMR (pre-RDN: 2.56 [2.18 to 3.20] vs 6 months
post-RDN: 2.36 [2.13 to 3.22]; P = 0.22). No significant
change was observed in WR (pre-RDN: 15.0 [10.5 to
18.5] vs 6 months post-RDN: 13.0 [6.0 to 22.0]; P =
0.22) (Table 2).
Primary Safety Endpoints
There were no peri-procedural complications. No
adverse events including death, stroke, or renal artery
stenosis occurred during 6-month follow-up. Renal
function remained unchanged, and estimated glomerular
filtration rate (eGFR) was 76 ± 17 mL/min pre-RDN vs
75 ± 18 mL/min at 6-month follow-up (P = 0.68).
Secondary Endpoints
Outcome on angina and quality
of life. CCS class improved significantly from 3.00 ±
0.47 (pre-RDN) to 1.80 ± 0.92 at 6-month follow-up, P
= 0.005.
Table 1. Baseline characteristics
Total study population N=10
Age, years 57 ± 11
Male n, (%) 9 (90)
BMI, kg/m2 26.6 ± 5.0
eGFR, mL/min 76 ± 17




Smoker, current 3 (30)
Family history of premature CVD 7 (70)
Cardiovascular history (%)
Prior MI 7 (70)
Prior PCI 8 (80)
24h ABPM, mmHg 121 ± 16/72 ± 8
Office BP, mmHg 143 ± 19/80 ± 10







LVEF, % 59 ± 9.6
LVEDD, mm 50 ± 6.1
LVESD, mm 34 ± 4.9
Pharmacological therapy, n (%)
Nitrates, 10 (100)
Calcium channel blockersa 8 (80)a





Variables are presented in mean ± SD or %
ABPM, ambulatory blood pressure measurement; BP, blood
pressure; BMI, body mass index; CCS, Canadian
cardiovascular society grading of angina pectoris; CVD,
cardiovascular disease; eGFR, estimated glomerular filtration
rate; MI, myocardial infarction; LVEF, left ventricular ejection
fraction; LVEDD, left ventricular end-diastolic diameter;
LVESD, left ventricular end-systolic diameter; PCI,
percutaneous coronary intervention
aN=2 were intolerant for calcium channel blockers
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The SAQ results showed significant improvements
in 3/5 subscales at 3- and 6-month follow-up; patients
were less limited in daily activities due to angina; angina
frequency decreased significantly and quality of life
improved as compared to pre-RDN. Angina stability and
treatment satisfaction remained unchanged at 3- and 6-
month follow-up (Figure 2).
Blood pressure change. A numerical decrease
in both office- and ambulatory BP at 6 months was
found as compared to pre-RDN. Office BP changed from
143 ± 19/80 ± 10 mmHg pre-RDN to 132 ± 12/77 ±
7 mmHg at 6-month follow-up and 24h ABPM
decreased from 121 ± 16/72 ± 8mmHg to 112 ± 8/70
± 7 mmHg (P = ns for all).
Change in medication. During the course of
the study, long-acting nitrates and calcium channel
blockers were decreased or stopped in 4 patients, while
dosages were increased in 3 patients (Figure 3).
DISCUSSION
This present single-center pilot study demonstrated
that RDN might significantly improve quality of life at 6
months post-procedure. However, no significant change
was observed in cardiac sympathetic nerve activity as
assessed by 123I-MIBG at 6 months post-procedure.
The autonomic nervous system is a key regulator of
coronary vasomotion and an imbalance between the
sympathetic and parasympathetic nervous system has
been reported in patients with VSA.4,17,18 Provocation
testing with parasympathetic agents such as acetyl-
choline or ergonovine can be performed in an attempt to
confirm the diagnosis.19 In vitro, sympathetic agents like
Table 2. Cardiac sympathetic nerve activity measured by 123I-MIBG pre- and 6 months post-
procedure, expressed in median [IQR]
Pre-RDN 6 months P
Early HMR 2.74 [2.10–3.21] 2.57 [2.20–3.00] 0.76
Late HMR 2.56 [2.18–3.20] 2.36 [2.13–3.22] 0.22
WR 15.0 [10.5–18.5] 13.0 [6.0–22.0] 0.22
Variables are presented in mean ± SD
HMR, heart/mediastinum ratio; WR, washout rate
Figure 2. Seattle Angina Questionnaire (SAQ) SAQ scale (each scale is a score of 0 to 100,
wherein higher scores indicate better function or less angina/limitation and better quality of life).
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norepinephrine were used to test the severity of vaso-
constriction or spasm.20
In the present study, we directly assessed cardiac
sympathetic nerve activity by 123I-MIBG imaging, in
line with previous work demonstrating the potential use
of the technique in diagnosing VSA.21 123I-MIBG is a
physiologic analog of norepinephrine and acts selec-
tively on sympathetic nerve endings. By using cardiac
neurotransmission imaging, global information about
neuronal function can be expressed in early, but more
specifically in late HMR (reflecting the storage regional
distribution and release of 123I-MIBG); additionally, the
WR reflects the neuronal integrity or sympathetic tone.14
123I-MIBG uptake is quantified by calculating an HMR
after drawing regions of interest over the heart and
mediastinum. Normal values for HMR and WR are 2.5 ±
0.3 or greater and 20 ± 10% or less, respectively.22 Little
data are available on reference values in patients with
VSA. Taki et al. reported higher WR in patients with
VSA, probably due to increased sympathetic tone
resulting in increased turnover of MIBG or impaired
MIBG reuptake at the nerve endings.23,24 In addition,
Arbab et al. showed a late HMR of 1.80 ± 0.60 in nine
patients with VSA which was numerically lower as
compared to healthy controls (2.00 ± 0.36).25 In the
present study, pre-RDN HMR and WR were in line with
previously published reference values for healthy con-
trol groups. Even in the cohort of patients with positive
methylergonovine testing, mean late HMR was within
the normal range. Our observations question whether
HMR and WR in patients with VSA are truly signifi-
cantly different than in healthy controls. Of note, several
minor differences in imaging acquisition between this
and other studies should be acknowledged such as the
use of different collimators and radioactive compounds.
RDN has been studied since 2008 for its potential to
control blood pressure in patients with therapy resistant
hypertension, in which increased SNS activity has been
hypothesized to play an important role.26 Only very
recently, the results of several sham-controlled random-
ized trials demonstrated that the therapy, conducted
using a radiofrequency ablation catheter, might signif-
icantly decrease blood pressure.27 At the same time, a
series of studies were conducted to assess potential
pleiotropic effects of RDN.28,29 In the present study, we
attempted to further extend these findings in a cohort of
VSA patients without residual regular therapeutic
options. Given the limited options in objectively assess-
ing the severity of signs and symptoms of these patients,
we decided to further study the effect of RDN by using
123I-MIBG imaging. We hypothesized that post-RDN,
late HMR would increase and WR would decrease as
compared to pre-RDN.23,25 However, 6 months post-
RDN, we found no meaningful differences in both early
and late HMR and WR. The latter thus again questions
the role of the SNS in patients with VSA and the
potential of RDN to decrease intra-cardiac sympathetic
nerve activity.
Nevertheless, we found significant improvements in
angina class and quality of life at 6 months along with a
numerical decrease in BP. Following treatment with the
Paradise ultrasound balloon catheter, mean systolic
ambulatory blood pressure decreased with 9mmHg at
6 months. Although these figures did not reach statistical
Figure 3. Change in early and late heart-to-mediastinum ratio (HMR), and washout rates (WR) at
6-month follow-up. Legend: 5 patients were off beta-blocker (red bullet) during the course of the
study; 2 patients were on beta-blockers (same dose) at baseline and follow-up; 3 patients had beta-
blockers at baseline and their dosage was halved (N = 2) and N = 1 was stopped at 6 months. In 5
patients, no washout rate (WR) could be calculated at baseline or 6 months.
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significance in the present small single-center study, the
primary results of the RADIANCE SOLO trial assessing
the safety and efficacy of the same device in a
multicenter randomized sham-controlled setting showed
a significant decrease in daytime 24h ABPM as com-
pared to sham.30
LIMITATIONS
There are several limitations that should be taken
into account. First, results were based on a small pilot
study (N = 10) and should be considered hypothesis
generating. Using the results of the present study
along with the findings of previous work by Arbab
et al, a total of 70 patients would be needed to
support that RDN results in a 20% increase in late
HMR. Second, WR was calculated using one of the
methods as described by Flotats et al.,31 in which we
used the actual heart counts for calculating WR,
instead of ratios. Third, while the positive finding of a
significant reduction in angina class could be inter-
preted as promising, a potential placebo effect of the
treatment cannot be ruled out. In the recently pub-
lished sham-controlled ORBITA trial, a sham
procedure was able to significantly improve at least
3 subscales of the SAQ in patients with stable angina
and significant coronary artery disease.32 Fourth, anti-
anginal drug regimen was changed in 7/10 of the
patients [including an increase in nitrates (n = 1) and
diltiazem (n = 1)]. The impact of medication on
MIBG uptake should be taken into account. Jacobson
et al. described that the MIBG uptake could be
inhibited mostly by the use of beta-blockers such as
labetalol. Less evidence is available on the MIBG-
inhibitory effect by calcium channel blockers.33 Fur-
thermore, we acknowledge the fact that half of the
patients were still using selective beta-blockers that
were deliberately continued mostly due to the pres-
ence of a myocardial infarction in the past; in patients
(N = 3), beta-blockers were stopped or dosages
changed during follow-up. However, also in patients
in whom beta-blockers were either stopped or dosages
were changed, no change in late HMR was found
which was in line with results in patients without
changes in drug regimen.
Finally, we cannot exclude the fact that apart from
autonomic nervous system tone, multiple other alterna-
tive factors might play a role in triggering coronary
spasms such as endothelial dysfunction or microvascular
dysfunction.34,35
NEW KNOWLEDGE GAINED
The results in our study are promising and might
fuel future discussion on the potential use of RDN in
patients with vasospastic angina. Larger, randomized
trials are needed to demonstrate the value of 123I-MIBG
imaging post-RDN in patients with VSA.
CONCLUSION
RDN resulted in significant improvements in angina
class and quality of life at 6 months in patients with
refractory vasospastic angina. RDN did not result in
significant changes in cardiac sympathetic nerve activity
as measured using 123I-MIBG.
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